409. Journal Club: The ARREST-AF Trial with Drs. Prashanthan Sanders and Mehak Dhande

409. Journal Club: The ARREST-AF Trial with D...

Up next

444. Heart Failure: LVAD Part 2 with Dr. Mark Belkin and Dr. Chris Salerno

CardioNerds (Dr. Hamza Patel, Dr. Jenna Skowronski, and Dr. Apoorva Gangavelli) discuss advanced heart failure and LVAD management with Dr. Mark Belkin, Advanced Heart Failure & Transplant Cardiologist, and Dr. Chris Salerno, Cardiothoracic Surgeon. They explore the nuances of ri ...  Show more

443. Pulmonary Embolism: The Modern Approach to Pulmonary Embolism Care with Dr. Kenneth Rosenfield

This inaugural episode of the CardioNerds Pulmonary Embolism (PE) Series explores the evolution of acute PE care. Dr. Ibrahim Zahid, Dr. Dinu Balanescu, and Dr. Billy Joe Mullinax join guest expert Dr. Kenneth Rosenfield to discuss the shifting landscape of PE management. Pulmona ...  Show more

Recommended Episodes

PRAGUE-25 Trial: Catheter Ablation Versus Antiarrhythmic Drugs With Risk Factor Modification for Treatment of AF
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

<div class="OutlineElement Ltr SCXW209201394 BCX0">

<span class= "TextRun SCXW209201394 BCX0" lang="EN-US" xml:lang="EN-US" data-contrast="auto"><span class= "NormalTextRun SCXW209201394 BCX0">The PRAGUE-25</span> <span class="NormalTextRun ...

  Show more

Dapagliflozin in Patients Undergoing Transcatheter Aortic Valve Implantation
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

The DapaTAVI trial, conducted across 39 centers in Spain, is the first study to evaluate the use of sodium-glucose co-transporter-2 (SGLT-2) inhibitors, specifically dapagliflozin, in patients with heart failure undergoing transcatheter aortic valve implantation (TAVI). The trial ...  Show more

Review of the Primary Angioplasty in Myocardial Infarction Study Group trial
Cardiology Trials

N Engl J Med 1993;328:673-679Background: Previous trials established that thrombolysis improves mortality in patients with acute myocardial infarction, as seen in the GISSI-1 and ISIS-2 trials. However, thrombolysis has limitations, including an increased risk of bleeding and the ...  Show more

Sep 12 2025 This Week in Cardiology
This Week in Cardiology

More from ESC including: Valvular HD guidelines, a new drug class for HTN, myosin inhibition in HCM, vericiguat, and digoxin are the topic discussed by John Mandrola, MD. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit ...  Show more